← All trials
NCT03937479
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2019
- Primary completion
- Sep 30, 2019
- Completion date
- Sep 30, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 400
- Arms / groups
- 5 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Verona Pharma plcLead sponsor
- IQVIACollaborator
- LGC LimitedCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.